Market Place
Sourcing Support
Maplight Therapeutics Completes IPO With Full Underwriters Option
29 Oct 2025 //
GLOBENEWSWIRE
Novo-Backed Maplight Valued At $787M In Nasdaq Debut
27 Oct 2025 //
REUTERS
Maplight Goes Public Via $250M IPO To Fund Cobenfy Competitor
27 Oct 2025 //
FIERCE BIOTECH
Maplight Therapeutics Prices IPO
26 Oct 2025 //
GLOBENEWSWIRE
Maplight Illuminates $262M IPO Plans To Fund Cobenfy Competitor
07 Oct 2025 //
FIERCE BIOTECH
Maplight Therapeutics Initiates IPO Launch
06 Oct 2025 //
PR NEWSWIRE
Maplight Sustains Biopharma`s Ipo For Alzheimer`s, Schizophrenia
22 Sep 2025 //
BIOSPACE
MapLight Therapeutics Initiates Phase 2 Trial for Alzheimer
17 Sep 2025 //
PR NEWSWIRE
MapLight raises $373M to Plot Phase 2 journey for Cobenfy rival
29 Jul 2025 //
FIERCE BIOTECH
MapLight Therapeutics Secures $372.5M in Series D Funding
28 Jul 2025 //
PR NEWSWIRE
MapLight starts Phase 2 trial of M1/M4 Muscarinic Agonist
07 Jul 2025 //
PR NEWSWIRE
Maplight Report Ph 1 Result for Schizophrenia & Alzheimer’s Disease
02 Dec 2024 //
PR NEWSWIRE
Maplight Announces Completion Of Ph1 Trial For Novel M1/M4 Muscarinic Agonist
03 Jan 2024 //
PR NEWSWIRE
MapLight Therapeutics Closes $225 Million Series C Funding Round
30 Oct 2023 //
PR NEWSWIRE
Exclusive: Trailing Karuna, MapLight Therapeutics aims to improve schizophrenia
30 Oct 2023 //
ENDPTS
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.